Veronica Barbi

Dr. Veronica Barbi

ICS Maugeri SpA, SB
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
AMALESSIA MONGELLI
ALESSIA MONGELLI
VBVeronica Barbi
Veronica Barbi
MZMichela Gottardi Zamperla
Michela Gottardi Zamperla
SASandra Atlante
Sandra Atlante
LFLuana Forleo
Luana Forleo
Carlo GaetanoCarlo Gaetano
Carlo Gaetano
The SARS-CoV-2 infection determines the COVID-19 syndrome characterized, in the worst cases, by severe respiratory distress, pulmonary and cardiac fibrosis, inflammatory cytokine release, and immunosuppression. This condition has led to the death of about 2.15% of the total infected world population so far. Among survivors, the presence of the so-called persistent post-COVID-19 syndrome (PPCS) is a common finding. In COVID-19 survivors, PPCS presents one or more symptoms: fatigue, dyspnea, memory loss, sleep disorders, and difficulty concentrating. In this study, a cohort of 117 COVID-19 survivors (post-COVID-19) and 144 non-infected volunteers (COVID-19-free) was analyzed using pyrosequencing of defined CpG islands previously identified as suitable for biological age determination. The results show a consistent biological age increase in the post-COVID-19 population, determining a DeltaAge acceleration of 10.45 ± 7.29 years (+5.25 years above the range of normality) compared with 3.68 ± 8.17 years for the COVID-19-free population (p < 0.0001). A significant telomere shortening parallels this finding in the post-COVID-19 cohort compared with COVID-19-free subjects (p < 0.0001). Additionally, ACE2 expression was decreased in post-COVID-19 patients, compared with the COVID-19-free population, while DPP-4 did not change. In light of these observations, we hypothesize that some epigenetic alterations are associated with the post-COVID-19 condition, particularly in younger patients (< 60 years).

21 October 2020 in Clinical Epigenetics
Verified
Journal Article
Open access
PDF file
SASandra Atlante
Sandra Atlante
AMALESSIA MONGELLI
ALESSIA MONGELLI
VBVeronica Barbi
Veronica Barbi
Fabio MartelliFabio Martelli
Fabio Martelli
AFAntonella Farsetti
Antonella Farsetti
Carlo GaetanoCarlo Gaetano
Carlo Gaetano
Epigenetics is a relatively new field of science that studies the genetic and non-genetic aspects related to heritable phenotypic changes, frequently caused by environmental and metabolic factors. In the host, the epigenetic machinery can regulate gene expression through a series of reversible epigenetic modifications, such as histone methylation and acetylation, DNA/RNA methylation, chromatin remodeling, and non-coding RNAs. The coronavirus disease 19 (COVID-19) is a highly transmittable and pathogenic viral infection. The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which emerged in Wuhan, China, and spread worldwide, causes it. COVID-19 severity and consequences largely depend on patient age and health status. In this review, we will summarize and comparatively analyze how viruses regulate the host epigenome. Mainly, we will be focusing on highly pathogenic respiratory RNA virus infections such as coronaviruses. In this context, epigenetic alterations might play an essential role in the onset of coronavirus disease complications. Although many therapeutic approaches are under study, more research is urgently needed to identify effective vaccine or safer chemotherapeutic drugs, including epigenetic drugs, to cope with this viral outbreak and to develop pre- and post-exposure prophylaxis against COVID-19.

27 April 2021 in medRxiv
Verified
Preprint
Open access
PDF file
AMALESSIA MONGELLI
ALESSIA MONGELLI
VBVeronica Barbi
Veronica Barbi
MZMichela Gottardi Zamperla
Michela Gottardi Zamperla
SASandra Atlante
Sandra Atlante
LFLuana Forleo
Luana Forleo
Carlo GaetanoCarlo Gaetano
Carlo Gaetano
Introduction & Background the SARS-CoV-2 infection determines the COVID19 syndrome characterized, in the worst cases, by severe respiratory distress, pulmonary and cardiac fibrosis, inflammatory cytokines release, and immunosuppression. This condition has led to the death of about 2.15% of the total infected world population so far. Among survivors, the presence of the so-called persistent post-COVID19 syndrome (PPCS) is a common finding. In patients who survived the SARS-CoV-2 infection, overt PPCS presents one or more symptoms such as fatigue, dyspnea, memory loss, sleep disorders, and difficulty concentrating. The pathophysiology of PPCS is currently poorly understood, and whether epigenetic mechanisms are involved in this process is unexplored. Methods & Results In this study, a cohort of 117 COVID19 survivors (post-COVID19) and 144 non-infected volunteers (COVID19-free) were analyzed using pyrosequencing of defined CpG islands previously identified as suitable for biological age determination. Besides, telomere length (TL) and ACE2 and DPP-4 receptor expression were determined. The results show a consistent biological age increase in the post-COVID19 population (58,44 ± 14,66 ChronoAge Vs. 67,18 ± 10,86 BioAge, P<0,0001), determining a DeltaAge acceleration of 10,45 ± 7,29 years (+5.25 years above range of normality) compared to 3,68 ± 8,17 years for the COVID19-free population (P<0,0001). A significant telomere shortening parallels this finding in the post-COVID19 cohort compared to COVID19-free subjects (post-COVID19 TL: 3,03 ± 2,39 Kb vs. COVID19-free: 10,67 ± 11,69 Kb; P<0,0001). Additionally, ACE2 expression was decreased in post-COVID19 patients compare to COVID19-free, while DPP-4 did not change. Conclusion In light of these observations, we hypothesize that some epigenetic alterations are associated with the post-COVID19 condition, particularly in the youngers (<60 years). Although the consequences of such modifications on the long-term clinical outcome remain unclear, this finding might help indicating a direction to investigate the pathophysiology at the onset of the persistent post-COVID19 syndrome.

1 December 2017 in Journal of Human Evolution
Verified
Journal Article
Open access
CMCristiana Margherita
Cristiana Margherita
Gregorio OxiliaGregorio Oxilia
Gregorio Oxilia
VBVeronica Barbi
Veronica Barbi
DPDaniele Panetta
Daniele Panetta
JHJean-Jacques Hublin
Jean-Jacques Hublin
SBStefano Benazzi
Stefano Benazzi

Verified
Journal Article
Open access
PDF file
AMALESSIA MONGELLI
ALESSIA MONGELLI
SASandra Atlante
Sandra Atlante
VBVeronica Barbi
Veronica Barbi
TBTiziana Bachetti
Tiziana Bachetti
Fabio MartelliFabio Martelli
Fabio Martelli
Carlo GaetanoCarlo Gaetano
Carlo Gaetano
The WHO estimated around 41 million deaths worldwide each year for age-related non-communicable chronic diseases. Hence, developing strategies to control the accumulation of cell senescence in living organisms and the overall aging process is an urgently needed problem of social relevance. During aging, many biological processes are altered, which globally induce the dysfunction of the whole organism. Cell senescence is one of the causes of this modification. Nowadays, several drugs approved for anticancer therapy have been repurposed to treat senescence, and others are under scrutiny in vitro and in vivo to establish their senomorphic or senolytic properties. In some cases, this research led to a significant increase in cell survival or to a prolonged lifespan in animal models, at least. Senomorphics can act to interfere with a specific pathway in order to restore the appropriate cellular function, preserve viability, and to prolong the lifespan. On the other hand, senolytics induce apoptosis in senescent cells allowing the remaining non–senescent population to preserve or restore tissue function. A large number of research articles and reviews recently addressed this topic. Herein, we would like to focus attention on those chemical agents with senomorphic or senolytic properties that perspectively, according to literature, suggest a potential application as senotherapeutics for chronic diseases.

5 November 2024 in GeroScience
Verified
Journal Article
Open access
PDF file
Carlo GaetanoCarlo Gaetano
Carlo Gaetano
SASandra Atlante
Sandra Atlante
MZMichela Gottardi Zamperla
Michela Gottardi Zamperla
VBVeronica Barbi
Veronica Barbi
gentilini davidegentilini davide
gentilini davide
AFAntonella Farsetti
Antonella Farsetti
The COVID-19 pandemic has left a lasting legacy on human health, extending beyond the acute phase of infection. This article explores the evidence suggesting that SARS-CoV-2 infection can induce persistent epigenetic modifications, particularly in DNA methylation patterns, with potential long-term consequences for individuals’ health and aging trajectories. The review discusses the potential of DNA methylation-based biomarkers, such as epigenetic clocks, to identify individuals at risk for accelerated aging and tailor personalized interventions. Integrating epigenetic clock analysis into clinical management could mark a new era of personalized treatment for COVID-19, possibly helping clinicians to understand patient susceptibility to severe outcomes and establish preventive strategies. Several valuable reviews address the role of epigenetics in infectious diseases, including the Sars-CoV-2 infection. However, this article provides an original overview of the current understanding of the epigenetic dimensions of COVID-19, offering insights into the long-term health implications of the pandemic. While acknowledging the limitations of current data, we emphasize the need for future research to unravel the precise mechanisms underlying COVID-19-induced epigenetic changes and to explore potential approaches to target these modifications. Graphical Abstract: Impact of SARS-CoV-2 infection on the epigenetic landscape and individual response Following SARS-CoV-2 infection, individuals may develop either a normal immune response or an aberrant one, such as a cytokine storm. Both scenarios can result in long-lasting consequences, known as “long COVID.” This condition can reshape the epigenetic landscape by altering DNA methylation patterns, contributing to the “epigenetic drift.” This drift, further influenced by various factors, can lead to changes in gene expression, immune functionality, and disease susceptibility. One significant consequence of the epigenetic drift is the acceleration of biological aging, which can profoundly impact personalized medical interventions. Created with BioRender.com.